| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED MARCH 2021. Refer to TA754: Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | mogamulizumab (Poteligeo®) | |
| Formulation | 4 mg/ml concentrate for solution for infusion | |
| Reference number | 2792 | |
| Indication | For the treatment of adult patients with mycosis fungoides or Sezary syndrome who have received at least one prior systemic therapy |
|
| Company | Kyowa Kirin Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 09/05/2019 | |
| Date of issue | 14/05/2019 | |
| NICE guidance | TA754: Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome |
|